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Editorial on the Research Topic
Anatomy of Upper Airway and Neuronal Control of Pharyngeal Muscles in Obstructive
Sleep Apnea
This Research Topic summarizes the latest findings and new developments in mechanisms of
obstructive sleep apnea (OSA) pathophysiology. Many factors contribute to OSA. Both factors,
anatomically narrow pharyngeal airway and sleep-related suppression of pharyngeal muscle tone,
increase collapsibility of upper airway. In addition, the responsiveness of pharyngeal muscles to
negative pressure, low arousal threshold, and high loop gain (unstable ventilatory control in part
related to elevated ventilatory chemoreflex control) importantly contribute to OSA (1). The review
article by Deacon-Diaz and Malhotra discusses the increase in loop gain by intermittent hypoxia, a
hallmark of OSA, and the limitations/challenges of measuring of the loop gain in OSA patients.
In one elegant original paper, a novel non-invasive approach to measuring the collapsibility of
upper airway in unanesthetized rodents is described by Nishimura et al. This paper is an important
methodological contribution to basic research in OSA pathophysiology, as it describes succinctly
methods for studying the control of upper airway muscles during natural sleep and wakefulness.
Upper airway muscles are predominantly innervated and controlled by hypoglossal
motoneurons, which receive state-dependent modulatory inputs resulting in the highest
motoneuron activity during wakefulness that is decreased during slow wave sleep and maximally
suppressed during rapid-eye-movement (REM) sleep. The state-dependent reduction in the activity
of hypoglossal motoneurons leads to the sleep-related suppression of upper airway muscle tone, a
major non-anatomical contributor to OSA pathophysiology. The original paper by Curado et al.
describes the impact of chemogenetic inhibition of hypoglossal motoneurons on the inspiratory
flow in mice. The reduction in hypoglossal motoneuron activity markedly increased the occurrence
of flow limitation during sleep confirming a critical role of the tone of upper airway muscles in
OSA pathophysiology.
The neurotransmitter mechanisms of the suppression of hypoglossal motoneurons during REM
sleep have been investigated to help develop pharmacological treatment for OSA. Initially, two
major conflicting hypotheses, withdrawal of serotonergic excitation and occurrence of glycinergic
inhibition during REM sleep, stimulated studies to uncover these mechanisms. However, direct
evidence obtained using different animal models of OSA has suggested that a withdrawal of
noradrenergic excitation mediated by α1-adrenoceptors from hypoglossal motoneurons critically
contributes to the suppression of their activity during REM sleep (2, 3). In addition, cholinergic
inhibition has been suggested to play a major role in the motoneuron depression that was
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mediated by muscarinic receptors (4). However, the relative
effectiveness of these and other neurotransmitters could not
be evaluated because the effects of applied antagonists were
assessed using different approaches and/or calculations. In the
systematic review by Fenik, uniform calculations were applied
to all available experimental data obtained using receptor
antagonists to assess the involvement of neurotransmitters and
their receptors in suppression of the activity of hypoglossal
and other motoneurons during REM and non-REM sleep. One
major finding of these calculations suggests that the relative
contribution of the withdrawal of noradrenergic excitation
and cholinergic (muscarinic) inhibition to the depression
of hypoglossal motoneuron activity during REM sleep is
∼50% each; whereas glycinergic or serotonergic drives have
negligible or no contribution to the effect of sleep on
hypoglossal motoneurons.
A recent proof-of-concept trial on unselected OSA
patients demonstrates that it is possible to improve OSA
significantly at least for one night by systemic administration of
noradrenaline reuptake inhibitor atomoxetine in combination
with a muscarinic antagonist oxybutynin (5). This finding is a
notable example of a high translational value of the knowledge
that is accumulated in basic research and applied to the
clinical trials. It also gives motivation to go forward with more
detailed studies that will focus on modulatory inputs to both
noradrenergic and cholinergic neural pathways to hypoglossal
motoneurons, which will provide information for additional
options of pharmacological treatment of OSA. A thorough
review by Rukhadze and Fenik of the neuroanatomical data of
the noradrenergic and cholinergic control of state-dependent
activity of hypoglossal motoneurons provides groundwork for
such studies. Only through further work into basic mechanisms
underlying OSA disease pathogenesis new therapeutic targets are
likely to emerge.
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